Elisa Agostinetto

2.6k total citations · 1 hit paper
85 papers, 1.5k citations indexed

About

Elisa Agostinetto is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Elisa Agostinetto has authored 85 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 42 papers in Pulmonary and Respiratory Medicine and 33 papers in Cancer Research. Recurrent topics in Elisa Agostinetto's work include HER2/EGFR in Cancer Research (29 papers), Advanced Breast Cancer Therapies (26 papers) and Breast Cancer Treatment Studies (26 papers). Elisa Agostinetto is often cited by papers focused on HER2/EGFR in Cancer Research (29 papers), Advanced Breast Cancer Therapies (26 papers) and Breast Cancer Treatment Studies (26 papers). Elisa Agostinetto collaborates with scholars based in Italy, Belgium and United States. Elisa Agostinetto's co-authors include Evandro de Azambuja, Martine Piccart, Matteo Lambertini, Daniel Eiger, Armando Santoro, Lucia Del Mastro, Joseph Gligorov, Véronique Debien, Philippe Aftimos and Christos Sotiriou and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and JNCI Journal of the National Cancer Institute.

In The Last Decade

Elisa Agostinetto

79 papers receiving 1.5k citations

Hit Papers

Evidence-based approaches for the management of side-effe... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer
    2021 168 citations Maria Alice Franzoi, Elisa Agostinetto et al. profile →

Peers

Elisa Agostinetto
Ji‐Yeon Kim South Korea
Musa Mayer United States
Uma Krishnamurti United States
Laura Pizzuti Italy
Cuizhi Geng China
Theresa L. Werner United States
Tao Sun China
Felix E. de Jongh Netherlands
Michael Hubalek Austria
Alejandra Perez United States
Ji‐Yeon Kim South Korea
Elisa Agostinetto
Citations per year, relative to Elisa Agostinetto Elisa Agostinetto (= 1×) peers Ji‐Yeon Kim

Countries citing papers authored by Elisa Agostinetto

Since Specialization
Citations

This map shows the geographic impact of Elisa Agostinetto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elisa Agostinetto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elisa Agostinetto more than expected).

Fields of papers citing papers by Elisa Agostinetto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elisa Agostinetto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elisa Agostinetto. The network helps show where Elisa Agostinetto may publish in the future.

Co-authorship network of co-authors of Elisa Agostinetto

This figure shows the co-authorship network connecting the top 25 collaborators of Elisa Agostinetto. A scholar is included among the top collaborators of Elisa Agostinetto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elisa Agostinetto. Elisa Agostinetto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Matos, Leonor Vasconcelos de, Elisa Agostinetto, Matteo Lambertini, et al.. (2025). Brain imaging screening in metastatic breast cancer: patients’ and physicians’ perspectives. The Breast. 84. 104558–104558.
3.
Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2025). Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI Journal of the National Cancer Institute. 117(6). 1198–1208. 3 indexed citations
4.
Arecco, Luca, Elisa Agostinetto, Maria Alice Franzoi, et al.. (2025). Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance. ESMO Open. 10(5). 105057–105057. 3 indexed citations
5.
Agostinetto, Elisa, Georg Pfeiler, Dominik Hlauschek, et al.. (2025). Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109). ESMO Open. 10(1). 104096–104096. 1 indexed citations
6.
Lambertini, Matteo, Eva Blondeaux, Elisa Agostinetto, et al.. (2024). Clinical behavior of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing: Results from an international cohort study.. Journal of Clinical Oncology. 42(16_suppl). 10503–10503. 1 indexed citations
7.
Marta, Guilherme Nader, Marta Monteforte, Elisa Agostinetto, et al.. (2024). Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis. ESMO Open. 9(3). 102390–102390. 24 indexed citations
8.
9.
Hamy, Anne‐Sophie, Sabine C. Linn, Rinat Bernstein‐Molho, et al.. (2024). 266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study. ESMO Open. 9. 103325–103325.
10.
Buisseret, Laurence, Yacine Barèche, David Venet, et al.. (2024). The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab. ESMO Open. 9(5). 102964–102964. 4 indexed citations
11.
Debien, Véronique, Virginie Adam, Elisa Agostinetto, et al.. (2023). DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer. Future Oncology. 19(24). 1655–1667. 3 indexed citations
12.
Jacobs, Flavia, et al.. (2023). Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer. Cancers. 15(11). 2933–2933. 15 indexed citations
13.
Jacobs, Flavia, Elisa Agostinetto, Rosalba Torrisi, et al.. (2023). Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib. Journal of Clinical Medicine. 12(5). 1775–1775. 6 indexed citations
14.
Agostinetto, Elisa, Mariana Brandão, Denis Larsimont, et al.. (2023). Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer.. Journal of Clinical Oncology. 41(16_suppl). 522–522. 1 indexed citations
15.
Agostinetto, Elisa, Matteo Lambertini, Françoise Rothé, et al.. (2022). Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO Precision Oncology. 6(6). e2200148–e2200148. 48 indexed citations
16.
Agostinetto, Elisa, Guilherme Nader Marta, Marianne Paesmans, et al.. (2022). ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast. Future Oncology. 18(22). 2383–2392. 15 indexed citations
17.
Tagliamento, Marco, Elisa Agostinetto, Roberto Borea, et al.. (2021). VISTA: A Promising Target for Cancer Immunotherapy?. SHILAP Revista de lepidopterología. Volume 10. 185–200. 41 indexed citations
18.
Tagliamento, Marco, Elisa Agostinetto, Marco Bruzzone, et al.. (2021). Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 163. 103365–103365. 44 indexed citations
19.
Sanctis, Rita De, Laura Giordano, Elisa Agostinetto, et al.. (2021). Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab. The Breast. 57. 80–85. 7 indexed citations
20.
Gerussi, Alessio, Ambra Natalini, Fabrizio Antonangeli, et al.. (2021). Immune-Mediated Drug-Induced Liver Injury: Immunogenetics and Experimental Models. International Journal of Molecular Sciences. 22(9). 4557–4557. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ji‐Yeon Kim Breakdown of academic impact, for papers by Musa Mayer Breakdown of academic impact, for papers by Uma Krishnamurti Breakdown of academic impact, for papers by Laura Pizzuti Breakdown of academic impact, for papers by Cuizhi Geng Breakdown of academic impact, for papers by Theresa L. Werner Breakdown of academic impact, for papers by Tao Sun Breakdown of academic impact, for papers by Felix E. de Jongh Breakdown of academic impact, for papers by Michael Hubalek Breakdown of academic impact, for papers by Alejandra Perez
Rankless by CCL
2026